Back to top

CleanCap® EGFP mRNA (5moU) - (L-7201)

CleanCap®Enhanced Green Fluorescent Protein mRNA (5-methoxyuridine)
In stock
default
L-7201
Product SKU Unit Size Price Qty
L-7201-100 100 µg
$407.00
L-7201-1000 1 mg
$2,213.00
L-7201-5 5 x 1 mg
$7,964.00

0

Description

The EGFP mRNA will express an enhanced version of the green fluorescent protein, originally isolated from the jellyfish, Aequorea victoria. EGFP is a commonly used direct detection reporter in mammalian cell culture, yielding bright green fluorescence with an emission peak at 509 nm.

This mRNA is capped using CleanCap, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, modified with 5-methoxyuridine and optimized for mammalian systems. It mimics a fully processed mature mRNA.

Product details
Catalog No L-7201
Purity Passes Agarose Gel Mobility
Length 996 nucleotides
Base Composition Fully substituted with 5-Methoxy-U
Concentration 1.0 mg/mL
Buffer 1 mM Sodium Citrate pH 6.4
Conversion Factor 40 µg/OD260
Recommended Storage At or below -40°C
Application Reporter Genes
Cap AG Start, Cap 1, CleanCap
Other Name(s) CleanCap®Enhanced Green Fluorescent Protein mRNA (5-methoxyuridine)
Technical documents

L-7201 Safety Data Sheet

L-7201 Product Insert

CleanCap EGFP ORF Sequence

Products faqs

They all contain an optimal 5′ Cap 1 found in higher eukaryotes for their functionality and stability. They also contain a synthetic 5′ UTR with a strong Kozak sequence for efficient translation and a 3′ UTR derived from mouse alpha-globin. Their key differences lie in the type of CleanCap® analog used and the sequence compositions, which may affect their protein expression and immunogenicity.

 

CleanCap® mRNAs

CleanCap® mRNAs (5moU)

CleanCap® M6 mRNAs (N1MePsU)

Expression system

Mammalian

Mammalian

Mammalian

5′ cap

Cap 1

Cap 1

Cap 1

Cap analog

CleanCap® AG

CleanCap® AG

CleanCap® M6

5′ and 3′ UTRs

Included

Included

Included

Poly(A) tail

120 nt

120 nt

120 nt

Sequence composition

Unmodified uridines

Uridines substituted with 5-methoxyuridines

Uridines substituted with N1-methylpseudouridines

Protein expression

High

High

Highest

Immunogenicity

Normal

Reduced

Lowest

 

It is TriLink’s proprietary in vitro transcription method that produces high-quality, high-yield mRNAs from a broad range of sequences. It has been optimized to minimize dsRNA and improve in vivo protein expression from the resulting mRNAs. Please see here for more information.

Our catalog mRNAs are intended for research use and manufactured with procedures in place to minimize endotoxin exposure. However, they are manufactured outside of a cleanroom and thus are not released with an endotoxin specification.  If you need mRNA released with an endotoxin specification or a higher grade of material, please contact [email protected].

We recommend storing the mRNAs at -400 C to -800 C. To minimize freeze-thaw cycles, aliquot the sample into single-use quantities on the first usage. If kept under these conditions, our catalog mRNAs have been shown to maintain stability for at least 2 years.

The sequence reported is just the ORF, start codon to stop codon, for our catalog mRNAs. It does not include the proprietary 5′ UTR, 3′ UTR, or the 120-nt poly-A tail. For full mRNA length and the length of the ORF please see the corresponding product insert.

Our catalog mRNAs are purified through DNase treatment to remove DNA templates, diafiltration to remove salts and small molecules, and oligo dT capture to remove impurities and retain species with poly(A) tails. 

We do not carry Cy5-labeled mRNAs as catalog products. You may order them as a custom mRNA by completing this request form.

We use the dot blot test, which is a qualitative test to determine the relative amount of dsRNA present in a sample. Generally, this test is performed to assess dsRNA levels in mRNAs before and after RP-HPLC purification.

We minimize the dsRNA level in our ready-to-use mRNAs by incorporating stringent processes that consist of:

  • In vitro transcription using our proprietary CleanScript™ method or the CleanCap® M6 protocol
  • Multiple post-IVT purification steps

We also assess dsRNA level in the sample by dot blot as part of quality analysis.

We look for a single main band running to approximately the correct length to pass the gel result.  Some factors such as modified NTPs can make a sample run slightly lower than the expected size.  Sometimes, sequence-related factors such as highly repetitive or UTP-rich regions (especially when modified UTP is used) can result in additional bands.  We take account of all these factors to confirm that the mRNA was manufactured appropriately and the band is sequence specific before passing the results.

The fragment analyzer reports the percent of smear with a chromatogram. The smear analysis corresponds to the full-length integrity of an mRNA sample.

We start by cleaving the 5′ end of the mRNAs, then use LCMS to determine the mass of capped and uncapped species by the following formula:

We use 40 as the extinction coefficient for our mRNAs. Assigning a sequence-specific extinction coefficient for mRNA can be problematic due to its dependence on length and sequence composition.  Factors like final buffer and temperature can also impact results.  Thus, it is standard to use 40 for all mRNA species and not to calculate a coefficient for each sequence as you would with an oligonucleotide.

Certificate of analysis

CoA search tool

Intellectual property

CleanCap capping technology For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes. For additional licensing restrictions, please see the license agreement at trilinkbiotech.com/cleancap-research-license. Patents and patent pending, see trilinkbiotech.com/legal-notices.

Mutant GFP mRNA These products are sold with a Limited Use Label License under sublicense with Life Technologies, Inc. Please review Limited License at trilinkbiotech.com/gfp-label-license.

Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission from TriLink No license under any patent or other intellectual property right of TriLink or its licensors is granted or implied by the purchase unless otherwise provided in writing.

TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.

References
  1. Fornaguera, Cristina; Guerra-Rebollo, Marta; Ángel Lázaro, Miguel; Castells-Sala, Cristina; Meca-Cortés, Oscar; Ramos-Pérez, Victor; Cascante, Anna; Rubio, Núria; Blanco, Jerónimo; Borrós, Salvador . mRNA Delivery System for Targeting Antigen-Presenting Cells In Vivo.
  2. Kauffman, Amy C.; Piotrowski-Daspit, Alexandra S.; Nakazawa, Kay H.; Jiang, Yuhang; Datye, Amit; Saltzman, W. Mark . Tunability of Biodegradable Poly(amine- co-ester) Polymers for Customized Nucleic Acid Delivery and Other Biomedical Applications.
  3. Estrada, K;Froelich, S;Wuster, A;Bauer, CR;Sterling, T;Clark, WT;Ru, Y;Trinidad, M;Nguyen, HP;Luu, AR;Wendt, DJ;Yogalingam, G;Yu, GK;LeBowitz, JH;Cardon, LR; . Identifying therapeutic drug targets using bidirectional effect genes
  4. Grun, M;Suberi, A;Shin, K;Lee, T;Gomerdinger, V;Moscato, Z;Piotrowski-Daspit, A;Saltzman, W; . PEGylation of Poly(amine-co-ester) Polyplexes for Tunable Gene Delivery
  5. Chi, F;Sharpley, MS;Nagaraj, R;Roy, SS;Banerjee, U; . Glycolysis-Independent Glucose Metabolism Distinguishes TE from ICM Fate during Mammalian Embryogenesis
  6. Gómez-Aguado, I;Rodríguez-Castejón, J;Beraza-Millor, M;Vicente-Pascual, M;Rodríguez-Gascón, A;Garelli, S;Battaglia, L;Del Pozo-Rodríguez, A;Solinís, MÁ; . mRNA-Based Nanomedicinal Products to Address Corneal Inflammation by Interleukin-10 Supplementation
  7. Yang, DC;Eldredge, AC;Hickey, JC;Muradyan, H;Guan, Z; . Multivalent Peptide-functionalized Bioreducible Polymers for Cellular Delivery of Various RNAs
  8. Tam, A;Leclair, P;Li, LV;Yang, CX;Li, X;Witzigmann, D;Kulkarni, JA;Hackett, TL;Dorscheid, DR;Singhera, GK;Hogg, JC;Cullis, PR;Sin, DD;Lim, CJ; . FAM13A as potential therapeutic target in modulating TGF-beta-induced airway tissue remodeling in COPD
  9. Legere, RM;Cohen, ND;Poveda, C;Bray, JM;Barhoumi, R;Szule, JA;de la Concha-Bermejillo, A;Bordin, AI;Pollet, J; . Safe and effective aerosolization of in vitro transcribed mRNA to the respiratory tract epithelium of horses without a transfection agent
  10. G . Nucleic Acid Delivery by Solid Lipid Nanoparticles Containing Switchable Lipids: Plasmid DNA vs. Messenger RNA
  11. Munson, M;O'Driscoll, G;Silva, A;L . A high-throughput Galectin-9 imaging assay for quantifying nanoparticle uptake, endosomal escape and functional RNA delivery
  12. Liu, K;Nilsson, R;L . An obesity model and corona multiomics analysis reveal high-density lipoprotein effects on lipid nanoparticle function
  13. Chi, F;Sharpley, MS;Nagaraj, R;Roy, SS;Banerjee, U; . Glucose metabolism distinguishes TE from ICM fate during mammalian embryogenesis
  14. Paramasivam, P;Stoter, M;Corradi, E;Dalla Costa, I; . Quantitative intracellular retention of delivered RNAs through optimized cell fixation and immuno-staining
  15. Estrada, K;Froelich, S;Wuster, A;Bauer, CR;Sterling, T; . Identifying therapeutic drug targets for rare and common forms of short stature
  16. Ulkoski, D;Munson, M;Jacobson, M;Palmer, C;Carson, C;Sabirsh, A;Wilson, J;Krishnamurthy, V; . High-Throughput Automation of Endosomolytic Polymers for mRNA Delivery
  17. Anderson, AJ; . Design, Synthesis, and Characterization of Functional Click Nucleic Acid Polymers and Conjugates for Biological Applications
  18. Sebastiani, F;Yanez Arteta, M;Lindfors, L;C . Screening of the binding affinity of serum proteins to lipid nanoparticles in a cell free environment
  19. Zhang, H;Bussmann, J;Huhnke, FH;Devoldere, J;Minnaert, AK;Jiskoot, W;Serwane, F;Spatz, J;R . Together is Better: mRNA Co-Encapsulation in Lipoplexes is Required to Obtain Ratiometric Co-Delivery and Protein Expression on the Single Cell Level
  20. Hao, S;Inamdar, VV;Sigmund, EC;Zhang, F;Stephan, SB;Watson, C;Weaver, SJ;Nielsen, UB;Stephan, MT; . BiTE secretion from in situ-programmed myeloid cells results in tumor-retained pharmacology
  21. Rui, Y;Wilson, DR;Tzeng, SY;Yamagata, HM;Sudhakar, D;Conge, M;Berlinicke, CA;Zack, DJ;Tuesca, A;Green, JJ; . High-throughput and high-content bioassay enables tuning of polyester nanoparticles for cellular uptake, endosomal escape, and systemic in vivo delivery of mRNA
  22. Darade, AR;Lapteva, M;Hoffmann, T;Mandler, M;Schneeberger, A;Kalia, YN; . Effect of mRNA Delivery Modality and Formulation on Cutaneous mRNA Distribution and Downstream eGFP Expression
  23. Shi, Y;Lu, Y;Qin, B;Jiang, M;Guo, X;Li, X;Liu, Y;Huang, J;Zhang, J;Luo, Z;Yin, H;Liu, H;Guan, G;Du, Y;Peng, L;You, J; . Antigen transfer from non-APCs to APCs impacts the efficacy and safety of protein- and mRNA- based vaccines
  24. Currie, J;Dahlberg, J;Eriksson, J;Schweikart, F;Nilsson, G; . Stability Indicating Ion-Pair Reversed-Phase Liquid Chromatography Method for Modified mRNA
  25. Liu, Y;Zhao, C;Sabirsh, A;Ye, L;Wu, X;Lu, H;Liu, J; . A Novel Graphene Quantum Dot-Based mRNA Delivery Platform
Show more